Table 2.
Results of the univariate analysis for overall survival and disease-free-survival (N=116)
| Overall survival |
Disease-free survival |
|||||
|---|---|---|---|---|---|---|
| Cohort |
Log-rank test |
Hazard ratioy† (95% CI) |
Cohort |
Log-rank test |
Hazard ratioy† (95% CI) |
|
| Covariate | N | P value* | N | P value* | ||
| Hemoglobin: >10 g/dL vs ≤10 g/dL‡ | 113 | .121 | 0.62 (0.333-1.143) | 109 | .268 | 0.65 (0.304-1.397) |
| Hydronephrosis: Yes vs No | 98 | .166 | 1.65 (0.878-3.114) | 95 | .560 | 1.27 (0.571-2.806) |
| Tumor size >6 cm vs ≤6 cm ‡ | 113 | .619 | 0.87 (0.492-1.525) | 109 | .253 | 1.52 (0.738-3.131) |
| Tumor grade | 98 | .766 | 94 | .318 | ||
| Grade 3 | 60 | 0.92 (0.275-3.061) | 59 | 1.49 (0.197-11.240) | ||
| Grade 2 | 31 | 1.16 (0.336-4.003) | 29 | 2.50 (0.325-19.277) | ||
| Grade 1 | 7 | 1.0 | 6 | 1.0 | ||
| Disease stage | 116 | .116 | 112 | .651 | ||
| Stage IVA | 7 | 1.52 (0.288-7.965) | 7 | 2.11 (0.383-11.592) | ||
| Stage IIIA-IIIB | 51 | 2.05 (0.486-8.655) | 48 | 1.06 (0.236-4.744) | ||
| Stage IIB | 48 | 1.02 (0.237-4.430) | 47 | 1.12 (0.252-4.938) | ||
| Stage I | 10 | 1.0 | 10 | 1.0 | ||
| Pelvic wall involvement: bilateral vs unilateral | 35 | .427 | 1.54 (0.526-4.514) | 33 | .129 | 3.46 (0.629-19.003) |
| Radiofrequency hyperthermia: yes vs no | 116 | .537 | 0.84 (0.488-1.453) | 112 | .097 | 1.88 (0.882-4.007) |
| Tandem use: yes vs no | 116 | .473 | 1.25 (0.684-2.265) | 112 | .429 | 0.75 (0.362-1.542) |
| Treatment duration: >10.1 wk vs ≤10.1 wk | 116 | .375 | 1.31 (0.720-2.388) | 112 | .961 | 0.98 (0.483-1.996) |
Abbreviation: CI = confidence interval.
*
P value for testing the equality of survival distributions among groups.
†
Univariate Cox proportional hazards regression model.
‡
Median value for all subjects.